［1］Siegel RL,KD Miller,A Jemal,et al.Cancer statistics,2015［J］.Cancer J Clin,2015,65(1):5-29.
［2］Scagliotti GV,P Parikh,J von Pawel,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer［J］.J Clin Oncol,2008，26(21):3543-3551.
［3］Fukuoka M,YL Wu,S Thongprasert,et al.Biomarker analyses and final overall survival results from a phase III,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)［J］.J Clin Oncol,2011,29(21):2866-2874.
［4］Mitsudomi T,S Morita,Y Yatabe,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomised phase 3 trial［J］.Lancet Oncol,2010,11(2):121-128.
［5］Zhou C,YL Wu,G Chen,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):A multicentre,open-label,randomised,phase 3 study［J］.Lancet Oncol,2011,12(8):735-742.
［6］Rosell R,E Carcereny,R Gervais,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre,open-label,randomised phase 3 trial［J］.Lancet Oncol,2012,13(3):239-246.
［7］Pao W,VA Miller,KA Politi,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain［J］.Plos Med,2005,2(3):73-73.
［8］Engelman JA,K Zejnullahu,T Mitsudomi,et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling［J］.Science,2007,316(5827):1039-1043.
［9］Yano S,W Wang,Q Li,et al.Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations［J］.Cancer Res,2008,68(22):9479-9487.
［10］Yano S,T Yamada,S Takeuchi,et al.Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort［J］.J Thoracic Oncol,2011,6(12):2011-2017.
［11］Takezawa K,V Pirazzoli,ME Arcila,et al.HER2 amplification:a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR(T790M) mutation［J］.Cancer Discovery,2012,2(10):922-933.
［12］Zhang Z,JC Lee,L Lin,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer［J］.Nature Genetics,2012,44(8):852.
［13］Kanda R,A Kawahara,K Watari,et al.Erlotinib resistance in lung cancer cells mediated by integrin beta 1/SRC/AKT-driven bypass signaling［J］.Cancer Res,2013,73(20):6243-6253.
［14］Yamamoto C,Y Basaki,A Kawahara,et al.Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations［J］.Cancer Res,2010,70(21):8715-8725.
［15］Ercan D,C Xu,M Yanagita,et al.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors［J］.Cancer Discovery,2012,2(10):934-947.
［16］Ohashi K,LV Sequist,ME Arcila,et al.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS,NRAS,or MEK1［J］.Proc Nat Acad Sci USA,2012,109(31):E2127-E2133.
［17］ Uramoto H,T Iwata,T Onitsuka,et al.Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma［J］.Anticancer Res,2010,30(7):2513-2517.
［18］Huang S,M Hoelzel,T Knijnenburg,et al.MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling［J］.Cell,2012,151(5):937-950.
［19］Yao Z,S Fenoglio,DC Gao,et al.TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer［J］.Proc Nat Acad Sci USA,2010,107(35):15535-15540.
［20］Sequist LV,BA Waltman,D Dias-Santagata,et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］.Sci Translational Med,2011,3(75)：75ra26.
［21］Garofalo M,G Romano,G Di Leva,et al.EGFR and MET receptor tyrosine kinase-altered microrna expression induces tumorigenesis and gefitinib resistance in lung cancers［J］.Nature Med,2012,18(1):74-82.
［22］Noguchi K,K Katayama,Y Sugimoto.Human ABC transporter ABCG2/BCRP expression in chemoresistance:basic and clinical perspectives for molecular cancer therapeutics［J］.Pharmacogenomics and Personalized Med,2014,7:53-64.
［23］Faber AC,RB Corcoran,H Ebi,et al.BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors［J］.Cancer Discovery,2011,1(4):352-365.
［24］Costa C,MA Molina,A Drozdowskyj,et al.The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial［J］.Clin Cancer Res,2014,20(7):2001-2010.
［25］Ng KP,AM Hillmer,CT Chuah,et al.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer［J］.Nat Med,2012,18(4):521-528.
［26］Kim GW,JS Song,CM Choi,et al.Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival［J］.Lung Cancer,2015,88(2):139-146.
［27］Zhong J,ZX Li,J Zhao,et al.Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients［J］.Thoracic Cancer,2014,5(6):509-516.
［28］Zhao M,Y Zhang,W Cai,et al.The BIM deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer［J］.Cancer,2014,120(15):2299-2307.
［29］Lee JH,YL Lin,WH Hsu,et al.Bcl-2-Like Protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer［J］.J Thoracic Oncol,2014,9(9):1385-1392.